Research information · No products for sale
Retatrutide: Clinical Trials and Research Status
An investigational medicine still in clinical trials – not an authorised UK treatment.
Published 20 October 2026 · Last reviewed 20 October 2026 · Editorial content by the Peptide Atelier UK team, not clinically reviewed
Editorial standards and corrections
Retatrutide is investigational and is not authorised as a treatment in the UK. It cannot be lawfully sold for human use. Peptide Atelier UK does not sell or supply it. This page is not medical advice; speak to a GP, pharmacist or other qualified healthcare professional.
Investigational status
Retatrutide is an investigational medicine developed by Eli Lilly. It acts on three hormone receptors: GIP, GLP-1 and glucagon. It has not been granted a marketing authorisation by the MHRA.
Clinical research
Phase 2 results have been published, and larger Phase 3 trials are under way to assess efficacy and safety in conditions including obesity and type 2 diabetes. Trial results should be read in full from peer-reviewed publications and trial registries rather than through social media summaries.
Evidence limitations
Until Phase 3 data are complete and reviewed by regulators, the balance of benefits and risks is not established. Trial participants receive pharmaceutical-grade product under medical supervision – conditions that do not apply to products sold online.
Products sold online
Anything sold online as retatrutide is unlicensed. A 'research' label does not make an unauthorised medicine lawful to sell for human consumption. If you are interested in taking part in research, speak to your GP or search an official trial registry.